3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Squamous Cell Carcinoma of Head and Neck
5
Prostatic Neoplasms
3
Head and Neck Neoplasms
3
Pancreatic Neoplasms
2
Neoplasms
2
Erectile Dysfunction
2
Carcinoma
2
Adenocarcinoma
2
Urogenital Neoplasms
1
Pyridoxine-dependent epilepsy
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurotoxicity Syndromes
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Glioblastoma
1
Gastric Adenocarcinoma
1
Esophageal Neoplasms
1
Astrocytoma
1
Abdominal Cancer
1
Interventions
padeliporfin
5
Nivolumab
3
vedolizumab
2
atezolizumab
2
anlotinib
2
Therapeutics
2
Surveys and Questionnaires
2
Riluzole
2
Radiotherapy
2
LDP-02
2
Ipilimumab
2
Infliximab
2
Immunoglobulin G
2
Genetic Testing
2
Fecal Microbiota Transplantation
2
Disulfides
2
Carboplatin
2
CT-P13
2
tislelizumab
1
relatlimab
1
prednylidene
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
ixabepilone
1
ferumoxtran-10
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urogenital Neoplasms
×
Tadalafil
×
Clear all
NCT06717711
2024-12-05
RCT_LiESWT
Regina Elena Cancer Institute
Phase 3
Recruiting
158 enrolled